News2025-03-14T18:43:32+00:00
News
Home»Company»News

News

Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.

3107, 2024

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL

July 31st, 2024|Gene & Cell Therapy Testing, News|

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period, according to a recent study...

304, 2024

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy

April 3rd, 2024|Gene & Cell Therapy Testing, News|

CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...

2503, 2024

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

March 25th, 2024|Gene & Cell Therapy Testing, News|

In a groundbreaking development that could revolutionize organ transplantation, eGenesis, a biotechnology company dedicated to addressing the global organ shortage crisis, has announced the successful transplantation of a genetically engineered porcine kidney into a living human recipient...

1403, 2024

qPCR or ddPCR for Bioanalysis? – Download our Comprehensive Guide

March 14th, 2024|Literature, News|

This comprehensive guide explores the essential tools of quantitative PCR (qPCR) and digital droplet PCR (ddPCR) in the biopharmaceutical industry, offering invaluable insights into their applications, strengths, and limitations. Download now to stay ahead of the curve in pharmaceutical research and development...

602, 2024

FDA issues final guidelines on incorporating human genome editing in gene therapy products

February 6th, 2024|FDA Guidance, Gene & Cell Therapy Testing, News|

The guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing and testing, nonclinical safety...

Go to Top